Emmis Communications Corp. (EMMS)
Indianapolis
What it does:
Owns radio stations throughout the U.S., including several in Indiana, and publishes magazines, including Indianapolis Monthly.
History:
Founded as Emmis Broadcasting with the purchase of one Indiana radio station in 1980 by Jeff Smulyan; went public in 1994.
Number of employees
: 1,300
When Bayh joined the board:
June 30, 1994
Stock prices:
$7.12 the day Bayh joined the board; closing price on Friday, $4.46. During the time Bayh has been a director, shares ranged from $62.34 to less than $5. The stock split 2-for-1 in February 2002.
Bayh stock ownership:
As of July, 72,832 shares of stock or stock options, less than 1 percent of the voting shares.
Bayh’s compensation in 2007:
$67,025, all in stock or options.
Emmis governance:
Five of seven directors are not company executives. In addition to Bayh, the independent directors are Peter A. Lund, a private investor and media consultant, former president and CEO of CBS and CBS Television and Cable; Lawrence B. Sorrel, managing partner and co-CEO of Tailwind Capital Group, an independent private equity firm; Greg A. Nathanson, former president of Emmis’ television division, now a media consultant; and Richard A. Leventhal, president and majority owner of LMCS, an investment, management and consulting company.
Dyax Corp. (DYAX)
Cambridge, Mass.
What it does:
Develops drugs to treat a rare plasma disorder and to prevent blood loss during coronary artery bypass surgery.
History:
Formed in 1995 and went public in August 2000.
Number of employees:
161
When Bayh joined the board:
July 16, 2003
Stock prices:
Closed at $3.92 a share the day Bayh joined the board; closing price on Friday, $3.74. During the time Bayh has been on the board, Dyax shares ranged from $14.14 to $2.73.
Bayh’s stock ownership:
As of March, 38,750 shares of stock options, less than 1 percent of the voting shares.
Bayh’s compensation in 2006:
$62,423, including $23,923 in stock options.
Dyax governance:
Seven of eight directors are not company executives. In addition to Bayh, the independent directors are James W. Fordyce, managing partner of MEDNA Partners, a private advisory firm; Mary Ann Gray, owner of a consulting firm that advises public and private biotechnology companies and a former analyst and portfolio manager for Federated Kaufmann Fund, focusing on public and private health care investments; Thomas L. Kempner, former chairman and CEO of Loeb Partners Corp., an investment banking firm; Constantine E. Anagnostopoulos, a retired corporate officer of Monsanto Co.; Henry R. Lewis, retired executive of Dennison Manufacturing Co.; David J. McLachlan, former executive vice president and chief financial officer of Genzyme Corp.
WellPoint Inc. (WLP)
Indianapolis
What it does:
Operates managed health care plans for employers, individuals, and Medicaid and Medicare programs.
History:
WellPoint Health Networks merged with rival Indianapolis-based Anthem in late 2004 in a $20.8 billion deal. WellPoint become the nation’s second-largest insurance company.
Number of employees:
42,000
When Bayh joined the board:
2001. She was a director of Anthem from 1998 to May 2003.
Stock prices:
$20 to $25 per share in 2001; closing price on Friday, $86.16. During the time Bayh has been on the board, shares ranged from $20 to $85.07. Split 2-for-1 in 2007.
Bayh’s stock ownership:
As of January, 8,552 shares or options, less than 1 percent of the voting shares.
Bayh’s compensation in 2006:
$324,250, including $249,944 in stock or options.
WellPoint governance:
Fourteen of 16 board members are independent. In addition to Bayh, they are Sheila P. Burke, deputy secretary and chief operating officer of the Smithsonian Institution and former chief of staff to then-Senate Majority Leader Bob Dole; Victor S. Liss, former president of Trans-Lux Corp.; Jane G. Pisano, former president of the Natural History Museum of Los Angeles County and former senior vice president of the University of Southern California; George A. Schaefer Jr., former CEO of Fifth Third Bancorp; Jackie M. Ward, founder and former president of Computer Generation Inc.; John E. Zuccotti, attorney in the real estate department of Weil, Gotshal & Manges; William H.T. Bush, founder and chairman of Bush-O’Donnell & Co.; Warren Y. Jobe, former senior vice president of Southern Co.; William G. Mays, president and CEO of Mays Chemical Co.; former Sen. Donald W. Riegle Jr., chairman of APCO Government Affairs; William J. Ryan, former president of TD Banknorth Inc.; Julie A. Hill, a business consultant; and Ramiro G. Peru, executive vice president and CFO of Phelps Dodge Corp.
Curis Inc. (CRIS)
Cambridge, Mass.
What it does:
Makes pharmaceuticals, particularly drugs that help repair tissues and organs. It focuses on cancer, neurological disorders, kidney and heart diseases and hair-growth regulation.
History:
Formed in 2000 when three biotech firms merged.
Number of employees:
50
When Bayh joined the board:
Oct. 19, 2000
Stock prices:
Closed at $12.88 the day Bayh was added to the board; closing price Friday, $1.14. During the time Bayh has been a director, shares ranged from $12.88 to 54 cents.
Bayh’s stock ownership:
226,250 shares or options, less than 1 percent of the voting shares.
Bayh’s compensation for 2006:
$156,942, including $124,942 in stock or options.
Curis governance:
Five of the eight board members are independent. In addition to Bayh, they are James R. McNab Jr., CEO and chairman of eNOS Pharmaceuticals; James R. Tobin, president of Boston Scientific Corp., a medical device company, and former president of Biogen; Martyn D. Greenacre, former CEO of Delsys Pharmaceutical Corp, and former president of of Zynaxis Inc., a biopharmaceutical company; and Kenneth I. Kaitin, associate professor of medicine and director of the Tufts Center for the Study of Drug Development.
Nastech Pharmaceutical Co. (NSTK)
Bothell, Wash.
What it does:
Develops drugs for osteoporosis, obesity, pain, inflammation and metabolic diseases; is working to develop nasal sprays to treat osteoporosis, deliver insulin and promote weight loss.
History:
Founded in the early 1980s; went public in 1984.
Number of employees:
150
When Bayh joined the board:
July 20, 2005
Stock prices:
Closed at $14.72 per share the day Bayh joined the board; closing price on Friday, $3.94. During Bayh’s tenure on the board, the shares fluctuated between $20.78 and $10.15.
Bayh’s stock ownership:
35,235 shares or options as of March, less than 1 percent of the voting shares.
Bayh’s compensation in 2006:
$264,283, including $253,498 in stock or options.
Nastech’s governance:
Seven of 10 directors are not executives. In addition to Bayh, the independent directors are Alexander D. Cross, pharmaceutical and biotechnology consultant who holds 109 patents; Myron Z. Holubiak, senior partner of 1-9 Doctors Inc. and former president of Roche Laboratories; Leslie D. Michelson, CEO of Prostate Health Management; John V. Pollock, executive vice president of United Bank; Bruce R. Thaw, president and CEO of Bulbtronics; and Devin N. Wenig, chief operating officer of Reuters.
Dendreon Corp. (DNDN)
Seattle
What it does:
Develops cancer treatments and is focusing on a drug to treat prostate cancer.
History:
Founded in 1992 as Activated Cell Therapy; went public in 2000. When the Food and Drug Administration delayed approval of its prostate drug, Provenge, a patient-advocate group sued the federal agency.
Number of employees:
250
When Bayh joined the board:
July 29, 2003, when Dendreon acquired Corvas International, another biopharmaceutical company. She had been a Corvas director since 2000.
Stock prices:
Dendreon closed at $6.38 the day Bayh joined the board; closing price on Friday, $7.33. During the time Bayh has been a director, shares fluctuated between $19.39 and $3.65.
Bayh’s stock ownership:
74,050 shares or options as of December 2006
Bayh’s compensation in 2006:
$136,104, including $97,104 in stock options
Dendreon’s governance:
Seven of nine directors are not company employees. In addition to Bayh, the independent directors are Gerardo Canet, former CEO of IntegraMed America Inc.; Bogdan Dziurzynsk, former member of the management of MedImmune Inc. and Immunex Corp.; Douglas G. Watson, CEO of Pittencrieff Glen Associates, a consulting firm, and former president of Novartis Corp. and Ciba-Geigy Corp.; Richard B. Brewer, founder of a management advisory and investment firm and president of a privately held biotechnology company; Ruth B. Kunath, former biotechnology portfolio manager for Vulcan Inc., a venture capital firm; and M. Blake Ingle, a partner of Inglewood Ventures, a venture capital firm and former president of a biopharmaceutical company.
Sources: Companies’ proxy statements; Securities and Exchange Commission; NASDAQ
